Madrigal Pharmaceuticals, Inc. (MDGL) Balance Sheet

The balance sheet has shifted from a nearly debt-free position in early 2024 to a D/E ratio of 0.66 by 2026Q2, a fourfold increase. This suggests the company is relying on external financing to support its commercial launch and ongoing losses, which may indicate a strategic bet on future profitability rather than a necessity-driven crunch, but investors should monitor the sustainability of this leverage as cash burn continues.

The debt increase appears to be tied to commercial scaling, but the company still generates negative retained earnings of -$2.2B, indicating that debt is not yet supported by accumulated profits. With a current ratio of 3.2, liquidity remains adequate, but the rising leverage could strain cash flows if revenue growth stalls or reimbursement challenges emerge, as flagged in prior income statement analysis.

The company's asset base is dominated by cash and receivables, with PPE representing less than 1.5% of total assets. This suggests a business model that outsources manufacturing and relies on intangible assets, but the low goodwill indicates that acquisitions have not been a major growth driver. The minimal PPE also implies low capital intensity, consistent with the cash flow statement's average CapEx under $2M per quarter.

The decline in equity reflects the company's ongoing unprofitability, with retained earnings deeply negative. While the company has not issued significant new shares recently, the equity base is shrinking, which could limit future borrowing capacity. The prior income statement analysis noted stock-based compensation averaging $22M per quarter, which may dilute existing shareholders and further pressure equity quality.

Although the current ratio remains above 3, the rapid decline in cash and the increase in liabilities suggest a tightening liquidity position. The company's cash runway, based on the prior quarter's operating cash flow of +$23.3M, appears adequate for the near term, but the volatility in working capital and ongoing losses could quickly erode the buffer. Investors should monitor whether the company can sustain positive operating cash flow as it scales.